Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial.

The development of effective vaccines against difficult disease targets will require the identification of new subunit vaccination strategies that can induce and maintain effective immune responses in humans. Here we report on a phase 1a clinical trial using the AMA1 antigen from the blood-stage Pla...

Full description

Bibliographic Details
Main Authors:	Hodgson, S, Choudhary, P, Elias, S, Milne, K, Rampling, T, Biswas, S, Poulton, I, Miura, K, Douglas, A, Alanine, D, Illingworth, J, de Cassan, S, Zhu, D, Nicosia, A, Long, C, Moyle, S, Berrie, E, Lawrie, A, Wu, Y, Ellis, R, Hill, A, Draper, S
Format:	Journal article
Language:	English
Published:	Nature Publishing Group 2014

Combining viral vectored and protein-in-adjuvant vaccines against the blood-stage malaria antigen AMA1: report on a phase 1a clinical trial.

Similar Items